Tanvex BioPharma, Inc. (6541.TW)
TWD 61.1
(2.52%)
TWD 61.1
(2.52%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 1.35 Billion TWD | 28.3% |
| 2022 | 1.05 Billion TWD | 326.96% |
| 2021 | -463.95 Million TWD | 23.18% |
| 2020 | -603.96 Million TWD | 71.03% |
| 2019 | -2.08 Billion TWD | -32.87% |
| 2018 | -1.56 Billion TWD | 21.89% |
| 2017 | -2 Billion TWD | -54.55% |
| 2016 | -1.29 Billion TWD | -71.42% |
| 2015 | -758.22 Million TWD | -274.12% |
| 2014 | -202.66 Million TWD | -20.54% |
| 2013 | -168.13 Million TWD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 827.81 Million TWD | -52.6% |
| 2024 Q1 | 1.74 Billion TWD | 29.28% |
| 2023 Q2 | 594.46 Million TWD | -56.53% |
| 2023 FY | 1.35 Billion TWD | 28.3% |
| 2023 Q4 | 1.35 Billion TWD | 38.44% |
| 2023 Q1 | 1.36 Billion TWD | 29.87% |
| 2023 Q3 | 975.87 Million TWD | 64.16% |
| 2022 Q2 | 529.62 Million TWD | 674.23% |
| 2022 Q4 | 1.05 Billion TWD | 39.15% |
| 2022 Q3 | 756.76 Million TWD | 42.89% |
| 2022 Q1 | -92.23 Million TWD | 80.12% |
| 2022 FY | 1.05 Billion TWD | 326.96% |
| 2021 FY | -463.95 Million TWD | 23.18% |
| 2021 Q4 | -463.95 Million TWD | 40.82% |
| 2021 Q1 | -159.12 Million TWD | 73.65% |
| 2021 Q2 | 98.53 Million TWD | 161.93% |
| 2021 Q3 | -783.92 Million TWD | -895.54% |
| 2020 Q4 | -603.96 Million TWD | -33.81% |
| 2020 Q1 | -1.52 Billion TWD | 26.82% |
| 2020 Q2 | -1.05 Billion TWD | 31.08% |
| 2020 Q3 | -451.37 Million TWD | 57.07% |
| 2020 FY | -603.96 Million TWD | 71.03% |
| 2019 Q1 | -718.78 Million TWD | 55.92% |
| 2019 Q2 | -872.66 Million TWD | -21.41% |
| 2019 FY | -2.08 Billion TWD | -32.87% |
| 2019 Q4 | -2.08 Billion TWD | -213.75% |
| 2019 Q3 | -664.45 Million TWD | 23.86% |
| 2018 Q4 | -1.63 Billion TWD | 35.5% |
| 2018 FY | -1.56 Billion TWD | 21.89% |
| 2018 Q3 | -2.52 Billion TWD | -173.03% |
| 2018 Q2 | -925.97 Million TWD | 29.79% |
| 2018 Q1 | -1.31 Billion TWD | 34.34% |
| 2017 Q4 | -2 Billion TWD | -126.32% |
| 2017 FY | -2 Billion TWD | -54.55% |
| 2017 Q1 | -835.29 Million TWD | 35.73% |
| 2017 Q2 | -566.16 Million TWD | 32.22% |
| 2017 Q3 | -887.55 Million TWD | -56.76% |
| 2016 Q3 | -3.14 Billion TWD | 10.34% |
| 2016 Q1 | 758.22 Million TWD | 200.0% |
| 2016 FY | -1.29 Billion TWD | -71.42% |
| 2016 Q2 | -3.5 Billion TWD | -562.44% |
| 2016 Q4 | -1.29 Billion TWD | 58.66% |
| 2015 Q4 | -758.22 Million TWD | 0.0% |
| 2015 Q2 | -1.29 Billion TWD | 0.14% |
| 2015 Q1 | -1.29 Billion TWD | -537.69% |
| 2015 FY | -758.22 Million TWD | -274.12% |
| 2014 FY | -202.66 Million TWD | -20.54% |
| 2014 Q4 | -202.66 Million TWD | 0.26% |
| 2014 Q3 | -203.2 Million TWD | 0.0% |
| 2014 Q1 | 164.57 Million TWD | 0.0% |
| 2013 FY | -168.13 Million TWD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Apex Biotechnology Corp. | -201.21 Million TWD | 771.436% |
| Sinphar Pharmaceutical Co.,Ltd. | 870.53 Million TWD | -55.196% |
| Panion & Bf Biotech Inc. | 193.2 Million TWD | -599.261% |
| Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 939.54 Million TWD | -43.796% |
| GenMont Biotech Incorporation | 2.71 Million TWD | -49716.704% |
| Abnova (Taiwan) Corporation | -415.8 Million TWD | 424.916% |
| Adimmune Corporation | 685.12 Million TWD | -97.193% |
| Polaris Group | -2.41 Billion TWD | 155.852% |
| Energenesis Biomedical CO.,LTD. | -246.6 Million TWD | 647.845% |
| UnicoCell Biomed Co., Ltd. | 54.43 Million TWD | -2382.14% |
| PELL Bio-Med Technology Co. Ltd. | 4.88 Million TWD | -27579.348% |